Syros Pharmaceuticals Inc. (SYRS) Financial Statements (2024 and earlier)

Company Profile

Business Address 35 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:139,526202,304130,369174,00091,40099,700
Cash and cash equivalents139,526167,46792,302173,98441,44149,886
Short-term investments 34,83738,067 49,97549,793
Other undisclosed cash, cash equivalents, and short-term investments   16(16)21
Restricted cash and investments     290638
Receivables    7  
Contract with customer, asset, after allowance for credit loss  1,6942,9792,324  
Other undisclosed current assets5,4547,3943,2372,22622,8231,396
Total current assets:144,980211,392136,585178,557114,513101,734
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization  76337597858
Operating lease, right-of-use asset12,18513,23114,10414,83115,821
Property, plant and equipment7,29811,35312,84414,21315,2103,861
Long-term investments and receivables   13,038   
Long-term investments   13,038   
Restricted cash and investments2,1193,0863,0863,0863,086290
Other noncurrent assets1,5925,3482,9411,966490881
Total noncurrent assets:23,19433,09446,35034,69335,4655,032
TOTAL ASSETS:168,174244,486182,935213,250149,978106,766
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,68916,15811,0429,98511,1047,083
Employee-related liabilities6,3445,7154,1742,985
Accounts payable11,5446,4113,6923,6035,8533,309
Accrued liabilities8,1459,7471,0066671,077789
Deferred revenue  4,33010,18112,2095,739
Debt6,667652912651,0379
Contract with customer, liability1,900
Other undisclosed current liabilities10,32510,2259,9946,1655,63610,537
Total current liabilities:36,68130,77831,50828,62423,51619,529
Noncurrent Liabilities
Long-term debt and lease obligation34,55640,64963,18064,48524,01822
Long-term debt, excluding current maturities34,55640,64940,25739,551  
Capital lease obligations22
Finance lease, liability   65356 
Liabilities, other than long-term debt18,52820,851 9,87722,6398,276
Deferred revenue    9,87722,639
Contract with customer, liability8,276
Operating lease, liability18,52820,85122,85824,57824,018
Total noncurrent liabilities:53,08461,50086,03874,36246,6578,298
Total liabilities:89,76592,278117,546102,98670,17327,827
Equity
Equity, attributable to parent16,662127,73685,21890,55379,18478,586
Common stock262061564334
Additional paid in capital739,443685,847548,815467,518372,100296,100
Accumulated other comprehensive income (loss)  102(79) 24(3)
Accumulated deficit(722,807)(558,233)(463,579)(377,021)(292,983)(217,545)
Total equity:16,662127,73685,21890,55379,18478,586
Other undisclosed liabilities and equity61,74724,472(19,829)19,711621353
TOTAL LIABILITIES AND EQUITY:168,174244,486182,935213,250149,978106,766

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues9,93614,88023,48815,0931,9822,050
Gross profit:9,93614,88023,48815,0931,9822,050
Operating expenses(138,924)(150,753)(122,908)(97,390)(79,723)(66,346)
Operating loss:(128,988)(135,873)(99,420)(82,297)(77,741)(64,296)
Nonoperating income6,8162,132874262,3032,017
Investment income, nonoperating6,8162,13287426  
Other nonoperating income     2,3032,017
Interest and debt expense(5,127)(4,134)(3,907)(1,792)(72) 
Loss from continuing operations before income taxes:(127,299)(137,875)(103,240)(83,663)(75,510)(62,279)
Income tax expense (1)(3)(1)(4)(28)(24)
Other undisclosed loss from continuing operations      
Loss from continuing operations:(127,300)(137,878)(103,241)(83,667)(75,538)(62,303)
Loss before gain (loss) on sale of properties:(103,241)(83,667)(75,538)(62,303)
Other undisclosed net income (loss)(37,274)43,22416,683(371)10024
Net loss:(164,574)(94,654)(86,558)(84,038)(75,438)(62,279)
Other undisclosed net loss attributable to parent      
Net loss available to common stockholders, diluted:(164,574)(94,654)(86,558)(84,038)(75,438)(62,279)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(164,574)(94,654)(86,558)(84,038)(75,438)(62,279)
Comprehensive loss:(164,574)(94,654)(86,558)(84,038)(75,438)(62,279)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(102)181(79)(24)2739
Comprehensive loss, net of tax, attributable to parent:(164,676)(94,473)(86,637)(84,062)(75,411)(62,240)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: